FDA adds fresh ‘breakthrough’ for Novartis' cancer combo Tafinlar and Mekinist
Just four months after adding an FDA OK to sell its combo of Tafinlar and Mekinist for non-small cell lung cancer with a BRAF V600E …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
